1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Shanghai Titan Scientific Co. Ltd. Class A

Shanghai Titan Scientific Co. Ltd. Class A

SSSE:688133
17.86
CNY
-0.50
(-2.72%)
-0.57EPS
3.47BMarket Cap
Oct 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.74
2.48
3.29
4.77
7.3
9.46
11.03
11.69
14.5
23.58
23.66
17.89
15.49
15.59
Basic EPS, GAAP
0.11
0.09
0.2
0.32
0.42
0.61
0.71
0.87
0.96
1.13
0.62
0.08
-0.19
-0.49
Free Cash Flow per Basic Share
-0.54
0.09
-0.21
-0.12
0.08
0.13
-0.59
-1.98
-2.53
-4.08
-5.04
-1.81
-0.29
- -
Dividend per Share
0.03
0.04
0.04
0.03
0.26
0.26
0.31
0.07
0.26
0.37
0.41
0.35
0.35
0.27
Book Value per Share
1.06
1.13
1.82
2.07
2.96
3.73
5.03
9.62
10.55
16.51
16.9
16.94
16.74
16.5
Tangible Book Value per Share
1.06
1.13
1.82
2.07
2.93
3.69
4.99
9.38
9.27
14.73
15.1
14.74
14.79
14.61
Basic Weighted Avg Shares
76
76
82
86
91
98
104
118
149
111
117
161
163
164
Sales/Revenue/Turnover
133
187
268
409
664
926
1,144
1,384
2,164
2,608
2,770
2,884
2,521
2,554
Operating Margin (%)
5.08
5.07
7.64
8.33
7.44
8.41
8.71
9.18
8.11
7.71
4.19
2.29
0.6
-0.84
Depreciation Expense
1
3
3
3
4
6
7
10
20
37
60
84
100
- -
Net Income, GAAP
8
7
17
28
39
60
74
103
144
125
73
13
-31
-80
Effective Tax Rate (%)
12.38
15.72
14.16
11.81
11.17
11.26
12.13
13.21
16.16
12.82
11.6
- -
- -
- -
Profit Margin (%)
6.09
3.71
6.21
6.74
5.8
6.47
6.48
7.42
6.65
4.79
2.62
0.45
-1.23
-3.14
Working Capital
70
75
141
163
240
324
477
1,305
1,241
2,250
1,960
1,683
1,445
1,362
LT Debt
- -
- -
- -
- -
- -
- -
- -
22
116
294
357
460
462
443
Total Equity
103
110
176
201
287
387
564
1,454
1,616
2,767
2,850
2,871
2,826
2,794
Return on Invested Capital (%)
- -
2.75
7.1
9.95
11.94
13.53
11.54
8.1
7.62
4.63
1.99
- -
- -
- -
Return on Capital (%)
- -
4.71
9.13
12.37
13.5
15.08
12.95
9.23
8.24
4.97
2.49
- -
- -
- -
Return on Common Equity (%)
- -
6.53
11.64
14.6
15.79
17.79
15.61
10.27
9.55
5.81
2.63
0.46
-1.12
-2.91

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,079
1,116
1,212
LT Borrowings
416
371
402
LT Finance Leases
46
40
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
164
164
164
Market Capitalization
3,641
3,246
3,475

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,975
2,924
3,033
Cash, Cash Equivalents & STI
916
774
848
Accounts Receivable, Net
667
735
768
Inventories
1,056
1,058
1,080
Total Current Liabilities
1,529
1,610
1,671
Payables & Accruals
- -
- -
- -
ST Debt
1,079
1,116
1,212
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.98%
16.9%
-1.56%
Free Cash Flow
-44.99%
-4.66%
-83.81%
Net Income, GAAP
-21.4%
-87.42%
-339.82%
Sales/Revenue/Turnover
27.34%
14.91%
-12.56%
Total Cash Common Dividend
131.41%
85.89%
1.34%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
664
732
729
758
2,884
2025
604
615
- -
673
2,521
2026
583
683
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.03
0.02
0.08
2025
0.03
0.03
- -
-0.26
-0.19
2026
-0.2
-0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.14
0.07
0.07
0.35
2025
0.08
0.13
- -
- -
0.35
2026
0.07
0.07
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Qing Zhang
Full Time Employees
1,776
Sector
Health technology
Industry
Medical specialties
Address
No. 89, Shilong Road Shanghai SH China 200232
IPO Date
Oct 30, 2020
Website
titansci.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Shanghai Titan Scientific Co., Ltd. (688133.SS) is a China-based company principally engaged in the research, development, production, and sales of laboratory products and supporting services for scientific researchers, quality control personnel, and industries including biomedicine, new materials, new energy, chemical chemistry, fine chemicals, food daily chemicals, analysis, and testing. The company offers core products and services encompassing scientific research reagents (high-end, general, analytical, biological), specialty chemicals (including organic compounds, inorganic compounds, intermediates, deuterated products, high-purity solvents), scientific research instruments and consumables (centrifuges, incubators, gel imaging systems, cell culture equipment, pipettes, chromatography consumables), safety and laboratory protective consumables, laboratory construction and integrated solutions (planning, design, procurement, installation, maintenance, relocation), and scientific research informatization software (such as Titan SRM and Titan LIMS); it operates through independent brands like Titan, TEDIA, Hzymes, Clinx, Magal, Radobio, and others, alongside third-party agency products via its Transoole.com platform. Founded in 2007 and headquartered at No. 89 Shilong Road, Xuhui District, Shanghai, China, the company maintains production bases in Songjiang and Fengxian, offices across 21 cities in China, and over 1,500 employees, with a focus on domestic supply chain security and global expansion. Recent developments include the 2024 acquisitions of RunDu Biology, MaiGao Instruments (centrifuges), and QinXiang Instruments, alongside establishing joint ventures Titan ChunYuan (pure water machines) and YiDa Biology (food rapid test reagents); in July 2025, it signed a letter of intent to acquire 100% of UK-based Apollo Scientific Ltd. (ASL) from Central Glass Co., Ltd. for approximately RMB 55.85 million to enhance overseas chemical reagent offerings and sales channels in Europe and the US; earlier, in 2021, it acquired a majority stake in Anhui TEDIA High Purity Solvents, expanding high-purity solvent capacity to 13,800 tons annually.